Tag: immunotherapy
Search News
Dr Luigi Ombrato awarded Cancer Research UK grant to understand how the seeds of secondary tumours grow
21st March 2024
Congratulations to Dr Luigi Ombrato who has been awarded a £700k grant to investigate the earliest stages of cancer spread.
Read more
New drug combination doubles survival for people with bladder cancer
25th October 2023
Clinical trial results from BCI and Barts NHS trust provide new hope for people with bladder cancer.
Read more
The REMODEL project: Remodelling tumour microenvironments to improve immunotherapy
12th October 2022
Professor Fran Balkwill from Barts Cancer Institute at Queen Mary University of London has received a UK Research and Innovation (UKRI) Frontier Research grant of over £2 million to investigate the most effective ways to remodel cancers to enhance the effects of immunotherapy.
Read more
In conversation with Professor Marco Gerlinger
20th May 2022
This International Clinical Trials Day, we spoke with Professor Marco Gerlinger. Professor Gerlinger and his team’s laboratory research focuses on understanding and overcoming drug resistance in bowel and gastro-oesophageal cancers, and identifying new and more effective ways to treat these cancers using immunotherapies and combination therapies.
Read more
Research highlighted in ASCO annual report on progress against cancer
2nd February 2021
Research led by Professors Peter Schmid and Thomas Powles from Barts Cancer Institute, Queen Mary University of London, has been selected by the American Society of Clinical Oncology (ASCO) for inclusion in the Clinical Cancer Advances 2021, the Society’s annual review of progress against cancer. The notable studies, which investigated the use of immunotherapy in the treatment of triple negative breast cancer and advanced bladder cancer, are featured as two of many remarkable milestones in clinical cancer research and care.
Read more
CAR T cell therapy for pancreatic cancer
22nd January 2021
Researchers from Barts Cancer Institute, Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer. Using this protein as a target, the team successfully created a CAR T cell therapy – a type of immunotherapy – that killed pancreatic cancer cells in a pre-clinical model.
Read more